BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20104211)

  • 1. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice.
    Dumonceaux J; Marie S; Beley C; Trollet C; Vignaud A; Ferry A; Butler-Browne G; Garcia L
    Mol Ther; 2010 May; 18(5):881-7. PubMed ID: 20104211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
    Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H
    Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking the myostatin signal with a dominant negative receptor improves the success of human myoblast transplantation in dystrophic mice.
    Fakhfakh R; Michaud A; Tremblay JP
    Mol Ther; 2011 Jan; 19(1):204-10. PubMed ID: 20700111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.
    Le Hir M; Goyenvalle A; Peccate C; Précigout G; Davies KE; Voit T; Garcia L; Lorain S
    Mol Ther; 2013 Aug; 21(8):1551-8. PubMed ID: 23752313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dystrophin restoration therapy improves both the reduced excitability and the force drop induced by lengthening contractions in dystrophic mdx skeletal muscle.
    Roy P; Rau F; Ochala J; Messéant J; Fraysse B; Lainé J; Agbulut O; Butler-Browne G; Furling D; Ferry A
    Skelet Muscle; 2016; 6():23. PubMed ID: 27441081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.
    Morine KJ; Bish LT; Pendrak K; Sleeper MM; Barton ER; Sweeney HL
    PLoS One; 2010 Feb; 5(2):e9176. PubMed ID: 20161803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of a dystrophin-like protein by exon skipping in vivo restores GABAA-receptor clustering in the hippocampus of the mdx mouse.
    Vaillend C; Perronnet C; Ros C; Gruszczynski C; Goyenvalle A; Laroche S; Danos O; Garcia L; Peltekian E
    Mol Ther; 2010 Sep; 18(9):1683-8. PubMed ID: 20588257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice.
    Denti MA; Incitti T; Sthandier O; Nicoletti C; De Angelis FG; Rizzuto E; Auricchio A; Musarò A; Bozzoni I
    Hum Gene Ther; 2008 Jun; 19(6):601-8. PubMed ID: 18500943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice.
    Lu-Nguyen N; Ferry A; Schnell FJ; Hanson GJ; Popplewell L; Dickson G; Malerba A
    Hum Mol Genet; 2019 Sep; 28(18):3091-3100. PubMed ID: 31179493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.
    Lu-Nguyen N; Dickson G; Malerba A
    Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
    Chu X; Li J; Qiao C; Wang J; Wang Y; Jiang XC; You H; Xiao X; Wang B
    FASEB J; 2021 Jun; 35(6):e21628. PubMed ID: 33982338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity.
    Trajanovska S; Ban J; Huang J; Gregorevic P; Morsch M; Allen DG; Phillips WD
    J Physiol; 2019 Sep; 597(18):4831-4850. PubMed ID: 31340406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice.
    Qiao C; Li J; Jiang J; Zhu X; Wang B; Li J; Xiao X
    Hum Gene Ther; 2008 Mar; 19(3):241-54. PubMed ID: 18288893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle.
    Roberts ML; Wells DJ; Graham IR; Fabb SA; Hill VJ; Duisit G; Yuasa K; Takeda S; Cosset FL; Dickson G
    Hum Mol Genet; 2002 Jul; 11(15):1719-30. PubMed ID: 12095914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression rate of myogenic regulatory factors and muscle growth factor after botulinum toxin A injection in the right masseter muscle of dystrophin deficient (mdx) mice.
    Botzenhart UU; Gerlach R; Gredes T; Rentzsch I; Gedrange T; Kunert-Keil C
    Adv Clin Exp Med; 2019 Jan; 28(1):11-18. PubMed ID: 30085421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
    Amthor H; Hoogaars WM
    Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
    Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.